Brokerages forecast that Amneal Pharmaceuticals Inc (NYSE:AMRX) will post sales of $465.95 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Amneal Pharmaceuticals’ earnings, with estimates ranging from $441.20 million to $474.50 million. Amneal Pharmaceuticals posted sales of $462.33 million during the same quarter last year, which suggests a positive year over year growth rate of 0.8%. The business is scheduled to issue its next earnings report on Thursday, August 8th.
According to Zacks, analysts expect that Amneal Pharmaceuticals will report full year sales of $1.91 billion for the current year, with estimates ranging from $1.82 billion to $1.96 billion. For the next year, analysts expect that the company will post sales of $1.97 billion, with estimates ranging from $1.86 billion to $2.04 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Amneal Pharmaceuticals.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.07). Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The company had revenue of $446.00 million for the quarter, compared to analyst estimates of $438.18 million. The business’s quarterly revenue was up 4.9% compared to the same quarter last year.
Several research firms have recently issued reports on AMRX. Cantor Fitzgerald cut their price objective on shares of Amneal Pharmaceuticals from $35.00 to $14.00 and set an “overweight” rating on the stock in a report on Wednesday, June 12th. Barclays initiated coverage on Amneal Pharmaceuticals in a research report on Tuesday, June 11th. They issued an “equal weight” rating and a $9.00 target price on the stock. Raymond James upgraded Amneal Pharmaceuticals from a “market perform” rating to a “strong-buy” rating and set a $13.00 target price on the stock in a research report on Tuesday, May 21st. They noted that the move was a valuation call. BMO Capital Markets dropped their target price on Amneal Pharmaceuticals from $14.00 to $13.00 and set a “market perform” rating on the stock in a research report on Friday, May 10th. Finally, Zacks Investment Research upgraded Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $16.73.
In related news, VP Andrew S. Boyer acquired 19,000 shares of the stock in a transaction on Monday, May 13th. The shares were acquired at an average price of $9.46 per share, for a total transaction of $179,740.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, SVP Joseph Todisco acquired 15,000 shares of the stock in a transaction on Monday, May 13th. The stock was bought at an average price of $9.88 per share, for a total transaction of $148,200.00. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 41,000 shares of company stock worth $387,300. 26.34% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Bessemer Group Inc. purchased a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at approximately $34,000. Quantamental Technologies LLC lifted its position in shares of Amneal Pharmaceuticals by 34.0% during the 1st quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock valued at $95,000 after buying an additional 1,700 shares in the last quarter. Meeder Asset Management Inc. lifted its position in shares of Amneal Pharmaceuticals by 785.6% during the 1st quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after buying an additional 10,347 shares in the last quarter. First Mercantile Trust Co. lifted its position in shares of Amneal Pharmaceuticals by 40.9% during the 1st quarter. First Mercantile Trust Co. now owns 11,932 shares of the company’s stock valued at $169,000 after buying an additional 3,461 shares in the last quarter. Finally, Amalgamated Bank purchased a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at approximately $174,000. Institutional investors and hedge funds own 36.05% of the company’s stock.
AMRX opened at $6.66 on Thursday. Amneal Pharmaceuticals has a 52-week low of $6.23 and a 52-week high of $24.48. The company has a current ratio of 2.11, a quick ratio of 1.37 and a debt-to-equity ratio of 3.44. The firm has a market capitalization of $1.99 billion, a P/E ratio of 7.16, a P/E/G ratio of 0.41 and a beta of 1.50. The firm’s 50-day moving average is $7.54.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Further Reading: Gap Down Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.